GSK’s Jemperli (Dostarlimab) Approved in the US for MSI-H/dMMR Locally Advanced Rectal Cancer

Shots: The US FDA has approved GSK’s Jemperli (dostarlimab) for adults with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) locally advanced rectal cancer, offering a new treatment option for eligible patients Approval was based on the P-II (AZUR-1) trial, in which 68% of evaluable patients (98/144) achieved a sustained clinical complete response at 12 months; no disease recurrences have been reported among responders after a median follow-up of more than two years Jemperli is a PD-1-blocking monoclonal antibody developed by GSK and is used across selected dMMR/MSI-H cancer indications; the US approval marks an important advance in immunotherapy for locally advanced rectal cancer Ref: Globenewswire |   Image: GSK  | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post GSK’s Jemperli (Dostarlimab) Approved in the US for MSI-H/dMMR Locally Advanced Rectal Cancer appeared first on PharmaShots.